IMR Press / FBL / Volume 21 / Issue 2 / DOI: 10.2741/4397

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Epidermal growth factor receptor-targeted therapy in colorectal cancer

Show Less
1 Department of Radiation Oncology, The Military General Hospital of Beijing PLA, Beijing, 100700, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2016, 21(2), 410–418; https://doi.org/10.2741/4397
Published: 1 January 2016
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

The epidermal growth factor receptor (EGFR) family plays an important role in colorectal cancer (CRC). EGFR participates in the key process of tumorigenesis and invasion, and its expression correlates with the prognosis of CRC. EGFR-targeted therapy has been widely utilized in stage III and IV CRC. The EGFR antibodies, cetuximab and panitumumab, are widely used in treatment of CRC. There are clinical trials and in vivo studies being carried out on the efficacy and mechanism of their action in CRC treatment. In this review, we will describe the EGFR-targeted therapy used in CRC, focusing on the efficacy and mechanisms of the most commonly used EGFR antibodies, cetuximab and panitumumab.

Keywords
Cetuximab
Panitumumab
Colorectal Cancer
Review
Share
Back to top